Equibles does not estimate personal net worth.
Earlier roles on record: CFO at Vir Biotechnology, Inc. (VIR) until August 3, 2026 and CFO at Caribou Biosciences, Inc. (CRBU) until September 27, 2024. Vir Biotechnology, Inc. reported in an 8-K filed July 24, 2026 that Jason O’Byrne resigned as Executive Vice President and Chief Financial Officer, effective August 3, 2026. Caribou Biosciences, Inc. reported in an 8-K filed September 3, 2024 that Jason O’Byrne resigned as Chief Financial Officer, effective September 27, 2024. The proxy statement of Vir Biotechnology, Inc. reports total compensation of $1,951,828 for Jason O’Byrne in fiscal 2025, including a base salary of $534,417. Disclosed compensation is on record for 4 fiscal years. Jason O’Byrne has spoken on 6 earnings calls across 1 company, most recently for Vir Biotechnology, Inc. on May 6, 2026. The companies whose calls Jason O’Byrne spoke on are classified in the Healthcare sector.
“On July 20, 2026, Jason O'Byrne, MBA, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (Vir Bio), informed Vir Bio that he will be stepping down from his role, effective August 3, 2026, to pursue another opportunity.”
“On September 1, 2024, Jason O'Byrne, the Chief Financial Officer of Caribou Biosciences, Inc. (the "Company"), informed the Company of his intent to resign from his position, effective September 27, 2024, to pursue another opportunity.”
“Before discussing the first quarter financials, I will share the latest news about our Stellis collaboration.”
“Let me first summarize the economic structure of the Estellus collaboration. In the U.S., we will co-develop and co-commercialize Veer 5500 under a 50-50 profit-sharing arrangement, with Veer Bio retaining the option to co-promote alongside Estellus.”
“With me today are Dr. Marianne DeBacker, our Chief Executive Officer, and Dr. Mark Eisner, our Chief Medical Officer. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws.”
“I'm pleased to share our second quarter financial performance and overall financial position. R&D expenses for the second quarter of 2025 were $97.5 million, which included $6.9 million of non-cash stock-based compensation expense.”
“I'm really pleased to share that our hard work on right-sizing the cost structure, improving efficiencies, and making thoughtful investment is paying off. Since late 2023, we've taken significant steps to streamline operations and focus on our most promising programs.”
2024-10-02–2026-08-03
Start not stated–2026-08-03
Start not stated–2024-09-27
Biotechnology · Healthcare
CFO
2024-10-02–2026-08-03
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Vir Biotechnology, Inc. (VIR) | Executive Vice President and Chief Financial Officer | $534,417 | $1,951,828 |
| 2024 | Vir Biotechnology, Inc. (VIR) | Executive Vice President and Chief Financial Officer | $130,492 | $1,919,827 |
| 2021 | Caribou Biosciences, Inc. (CRBU) | M.B.A. Chief financial officer | $358,580 | $3,449,030 |
| 2020 | Caribou Biosciences, Inc. (CRBU) | M.B.A. Chief financial officer | — | — |
